Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Keros Therapeutics Inc KROS

Biotechnology
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing novel therapeutics to treat a range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-B), family of proteins. Its lead product candidate, KER-050, is being developed for the treatment of low blood cell counts, or... see more

Recent & Breaking News (NDAQ:KROS)

Keros Therapeutics Presents Clinical Data from its KER-050 Program at the 65th American Society of Hematology Annual Meeting and Exposition

GlobeNewswire December 11, 2023

Keros Therapeutics to Present at Upcoming Healthcare Conferences

GlobeNewswire November 7, 2023

Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2023 Financial Results

GlobeNewswire November 6, 2023

Keros Therapeutics to Present at the 65th American Society of Hematology Annual Meeting and Exposition

GlobeNewswire November 2, 2023

Keros Therapeutics Presents Preclinical Data from its KER-065 Program at the 28th International Annual Congress of the World Muscle Society

GlobeNewswire October 4, 2023

Keros Therapeutics to Present at Upcoming Healthcare Conferences

GlobeNewswire September 5, 2023

Keros Therapeutics Reports Recent Business Highlights and Second Quarter 2023 Financial Results

GlobeNewswire August 7, 2023

Corrected: Keros Therapeutics to Host Conference Call and Webcast to Provide an Overview of TROPOS, the KER-012 Phase 2 Clinical Trial in Patients with Pulmonary Arterial Hypertension

GlobeNewswire July 27, 2023

Keros Therapeutics to Host Conference Call and Webcast to Provide an Overview of TROPOS, the KER-012 Phase 2 Clinical Trial in Patients with Pulmonary Arterial Hypertension

GlobeNewswire July 24, 2023

Keros Therapeutics Announces Update to Participation at the Goldman Sachs 44th Annual Global Healthcare Conference

GlobeNewswire June 12, 2023

Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical Data from its ALK2 Inhibitor Program at the 28th Annual Congress of the European Hematology Association

GlobeNewswire June 9, 2023

Keros Therapeutics to Present at Goldman Sach's 44th Annual Global Healthcare Conference

GlobeNewswire June 7, 2023

Keros Therapeutics Presents Preclinical and Clinical Data from its KER-012 Program at the American Thoracic Society International Conference

GlobeNewswire May 22, 2023

Keros Therapeutics to Present at the 28th Annual Congress of the European Hematology Association

GlobeNewswire May 11, 2023

Keros Therapeutics Reports Recent Business Highlights and First Quarter 2023 Financial Results

GlobeNewswire May 4, 2023

Keros Therapeutics Appoints Alpna Seth, Ph.D., to its Board of Directors

GlobeNewswire April 19, 2023

Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results

GlobeNewswire March 3, 2023

Keros Therapeutics to Present at Cowen's 43rd Annual Health Care Conference

GlobeNewswire March 1, 2023

Keros Therapeutics to Present at the SVB Securities Global Biopharma Conference

GlobeNewswire February 7, 2023

Keros Therapeutics Presents Clinical Data from its KER-050 and KER-047 Programs and Preclinical Data from its KER-050 and ALK2 Inhibitor Programs at the 64th American Society of Hematology Annual Meeting and Exposition

GlobeNewswire December 12, 2022